Constructing
efficient theranostic nanoparticles (NPs)
to improve
the therapeutic effect is a great challenge for triple-negative breast
cancer (TNBC). Theranostic NPs fail to reach an ideal therapeutic
effect due to high tumor solid stress and poor penetration in the
extracellular matrix. The LST-IR820-CaNPs are rationally designed
with desired therapeutic and ultrasound imaging properties, in which
polydopamine (PDA) in conjunction with glutathione (GSH) is used as
the template for CaCO3 mineralization in situ, equipped with the antihypertensive agent losartan (LST) and the
photosensitizer new indocyanine green (IR820). The biocompatibility,
drug release, photothermal and photodynamic effects, ultrasound imaging,
and antitumor evaluation are investigated thoroughly. Under near-infrared
(NIR) laser irradiation, LST-IR820-CaNPs produce singlet oxygen (1O2) and heat by converting absorbed laser energy.
The LST-IR820-CaNPs possess effective antitumor activity, which is
benefited from synergistic photothermal (PTT)/photodynamic (PDT) therapy
and exploitation of LST to reduce solid stress of the tumor through
depletion of collagen I. The NPs generate echogenic signals in an
acidic form from carbon dioxide (CO2) bubbles generated
from CaCO3, expressing stable ultrasound (US) imaging functions.
The LST-IR820-CaNPs exhibit negligible systemic toxicity and excellent
biocompatibility, thus being potential theranostic NPs for US imaging
and therapy of TNBC.